Zipalertinib achieved a 30.2% intracranial objective response rate and 72.1% intracranial disease control rate in 43 evaluable patients with EGFR-mutated lung cancer and active CNS metastases. The Phase 2 findings support further development, although the treatment remains investigational.
Johnson & Johnson’s final PAPILLON analysis found median overall survival of 34.3 months with first-line RYBREVANT plus chemotherapy versus 27.9 months with chemotherapy, but the protocol-specified comparison was not statistically significant. With 76% of eligible chemotherapy patients later receiving amivantamab, the trial has become a case study in how effective crossover can obscure overall-survival differences.
Zipalertinib’s pivotal REZILIENT3 data will debut at WCLC 2026 after the first-line lung cancer trial met its PFS endpoint.